Article info

Download PDFPDF

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
  1. Correspondence to:
    Mr E N van Roon
    Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR Leeuwarden, Netherlands; e.n.van.roonznb.nl
View Full Text

Citation

van Roon EN, Jansen TLTA, van de Laar MAFJ, et al
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis

Publication history

  • Accepted August 12, 2004
  • First published September 2, 2004.
Online issue publication 
March 15, 2005

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.